 |
MARK TORII
President, Schering-Plough Kabushiki Kaisha, (SPKK)
Schering-Plough Corporation
Osaka, Japan
Mark Torii is president of SPKK, the company's country operation in
Japan, and he is responsible for leading business operations there.
Japan is the second largest pharmaceutical market in the world, after
the U.S. market.
Torii joined Schering-Plough Corporation in 1995. Under his leadership,
several important new drugs have been launched, including REBETOL and
PEG-INTRON for the treatment of chronic hepatitis C; CLARITIN Redi-Tabs
for the treatment of allergies; and other key products have been submitted
for regulatory review, including TEMODAR, submitted for the treatment
of certain types of brain tumors; and ZETIA, submitted for the treatment
of high cholesterol.
Prior to joining Schering-Plough, Torii served as president and representative
director of Rhone-Poulenc Rorer, Japan and managing director of sales
& marketing for Nippon Roche, Japan. He has also held positions
at Hoffmann-La Roche in Basel, Switzerland and the United States.
Torii received a B.A. degree from Loyola College, Baltimore, Md., and
an M.B.A. from Sophia University, Tokyo. He also has participated in
advanced management programs at Harvard Business School, Cambridge,
Mass.
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.
|
|
